Shionogi, Inc
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 32
- Registration Number
- NCT07018492
- Locations
- πΊπΈ
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈAmerican Research Corporation dba Texas Liver Institute, San Antonio, Texas, United States
Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 16
- Registration Number
- NCT07012005
- Locations
- πΊπΈ
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
πΊπΈClinical Trials for Texas, LLC, dba Flourish Research, San Antonio, Texas, United States
A Study to Assess the Effects of BPN14770 on Rosuvastatin
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 14
- Registration Number
- NCT07011992
A Study of S-892216 in Participants With COVID-19
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 280
- Registration Number
- NCT06928051
A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 24
- Registration Number
- NCT06775730
- Locations
- πΊπΈ
Early Phase Clinical Unit Los Angeles, Glendale, California, United States
A Drug-drug Interaction Study of S-892216 Coadministered With Carbamazepime to Healthy Adult Participants
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 16
- Registration Number
- NCT06751017
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States
A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants
- Conditions
- RSV Infections
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 100
- Registration Number
- NCT06746051
- Locations
- πΊπΈ
SUNY Upstate Medical University, Syracuse, New York, United States
πΊπΈSeattle Children's Hospital, Seattle, Washington, United States
A Study of S-740792 in Healthy Adult Study Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 131
- Registration Number
- NCT06724978
- Locations
- πΊπΈ
Fortrea Clinical Research Unit, Inc., Daytona Beach, Florida, United States
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
- Conditions
- Jordan's SyndromePPP2R5D Neurodevelopmental Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 30
- Registration Number
- NCT06717438
- Locations
- πΊπΈ
Rush University Medical Center, Chicago, Illinois, United States
πΊπΈBoston Children's Hospital, Boston, Massachusetts, United States
πΊπΈSeattle Children's Hospital, Seattle, Washington, United States
A Study to Investigate Different Formulations of S-337395 in Healthy Adult Participants
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 50
- Registration Number
- NCT06270511
- Locations
- πΊπΈ
ICON Lenexa, Lenexa, Kansas, United States